典型文献
Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
文献摘要：
Triple-negative breast cancer(TNBC)has the worst prognosis among all molecular types of breast cancer.Because of the strong immunogenicity of TNBC cells,programmed death 1/programmed death ligand 1(PD-1/PD-L1)inhibitors,two kinds of immune checkpoint blockade agents,might help improve the prognosis of TNBC.However,how to better use PD-1/PD-L1 inhibitors and select patients who may benefit from treatment options remains controversial.This article summarizes published clinical studies in which PD-1/PD-L1 inhibitors were used in patients with advanced TNBC to explore how to maximize effectiveness of these medications.
文献关键词：
中图分类号：
作者姓名：
Yuehua Liang;Xiaoran Liu;Kun Li;Huiping Li
作者机构：
Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China
文献出处：
引用格式：
[1]Yuehua Liang;Xiaoran Liu;Kun Li;Huiping Li-.Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer)[J].中国癌症研究（英文版）,2022(02):117-130
A类：
B类：
Current,situation,programmed,death,protein,ligand,inhibitors,advanced,triple,negative,breast,cancer,Triple,TNBC,has,worst,prognosis,among,all,molecular,types,Because,strong,immunogenicity,cells,L1,two,kinds,immune,checkpoint,blockade,agents,might,help,improve,However,how,better,select,patients,who,may,benefit,from,treatment,options,remains,controversial,This,article,summarizes,published,clinical,studies,which,were,used,explore,maximize,effectiveness,these,medications
AB值：
0.631285
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
